Vivesto (VIVE) DNB Carnegie Småbolagsdag summary

Strategic direction and organizational changes

• New board and management have implemented a strategy focused on late preclinical to early clinical cancer development, targeting areas with unmet medical needs.

• Organization is streamlined to ensure the right expertise is available at the right time.

Pipeline and project updates

• Cantrixil is in late preclinical phase for hematological cancers, showing strong cytotoxic effects, especially in relapsed tumors.

• Pakalvet, a proprietary paclitaxel formulation, is in pilot studies for canine hemangiosarcoma and dose-finding studies for feline solid tumors.

• Apila remains in the portfolio, with ongoing partnership and development in China.

Recent results and clinical progress

• Interim analysis of Pakalvet in dogs with hemangiosarcoma showed a doubling of median survival compared to standard treatment.

• Early feline study results indicate good tolerability and promising efficacy at initial doses.

• Cantrixil demonstrated significant effects in AML, lymphoma, and multiple myeloma models, with synergistic effects when combined with standard therapies.